-
Safety
-
Actonel (risedronate sodium) Tablets
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- April 2008
| The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. Read about the new physician labeling format. |
| Sections Modified | Summary of Changes to Contraindications and Warnings |
|
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONS
PATIENT COUNSELING INFORMATION
PATIENT PACKAGE INSERT
|
WARNINGS AND PRECAUTIONS Upper Gastrointestinal Adverse Reactions ...Patients should discontinue use if new or worsening symptoms occur... Musculoskeletal Pain ...Consider discontinuing use if severe symptoms develop. |
The Apr 2008 label not available at this site.
-
-

